Bessemer Group
BBIO icon

Bessemer Group’s BridgeBio Pharma BBIO Stock Holding History

Bessemer Group’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$62K Sell
839
-1,247
-60% -$87.3K ﹤0.01% 1635
2026
Q1 		$155K Sell
2,086
-24
-1% -$1.74K ﹤0.01% 1444
2025
Q4 		$161K Hold
2,110
– – ﹤0.01% 1394
2025
Q3 		$110K Buy
2,110
+1,772
+524% +$86.4K ﹤0.01% 1253
2025
Q2 		$15K Buy
338
+170
+101% +$6.18K ﹤0.01% 1653
2025
Q1 		$6K Buy
168
+28
+20% +$944 ﹤0.01% 1939
2024
Q4 		$4K Hold
140
– – ﹤0.01% 2040
2024
Q3 		$4K Buy
+140
New +$3.67K ﹤0.01% 1980
2022
Q2 		– Sell
-77
Closed -$1K – 1875
2022
Q1 		$1K Hold
77
– – ﹤0.01% 1760
2021
Q4 		$1K Sell
77
-1,656
-96% -$70.1K ﹤0.01% 1798
2021
Q3 		$81K Hold
1,733
– – ﹤0.01% 975
2021
Q2 		$106K Hold
1,733
– – ﹤0.01% 935
2021
Q1 		$107K Buy
+1,733
New +$113K ﹤0.01% 876

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Bessemer Group's BBIO Position: Q2 2026 in Review

Bessemer Group reduced its BridgeBio Pharma (BBIO) stake by 60% in Q2 2026, selling an estimated $87.3K and leaving 839 shares worth $62K. The position accounts for ﹤0.01% of the portfolio, ranked #1635.

Bessemer Group first reported a position in BBIO in Q1 2021 and has held it in 13 quarters since. The position peaked at $161K in Q4 2025. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Bessemer Group held 839 shares of BridgeBio Pharma worth $62K as of Q2 2026.
  • Bessemer Group sold 1,247 BridgeBio Pharma shares in Q2 2026, an estimated $87.3K.
  • BridgeBio Pharma made up ﹤0.01% of Bessemer Group's portfolio in Q2 2026, its #1635 holding.
  • Bessemer Group first reported a position in BridgeBio Pharma in Q1 2021 and has held it in 13 quarters since.
  • Bessemer Group's BridgeBio Pharma position peaked at $161K in Q4 2025.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Bessemer Group's 13F filing for Q2 2026, filed 12 Aug 2026.